AN IN SILICO ANALYSIS OF FOLLICULIN AND FOLLICULIN INTERACTING PROTEINS RESPONSIBLE FOR SKIN TUMORS AND BIRT HOGG DUBÃ‰ SYNDROME. by Panchal, Hetalkumar J et al.
Panchal et al                                   Journal of Drug Delivery & Therapeutics; 2012, 2(4), 104    104 
© 2011, JDDT. All Rights Reserved                                                         ISSN: 2250-1177                                                    CODEN (USA): JDDTAO 
Available online at http://jddtonline.info 
RESEARCH ARTICLE 
AN IN SILICO ANALYSIS OF FOLLICULIN AND FOLLICULIN INTERACTING 
PROTEINS RESPONSIBLE FOR SKIN TUMORS AND BIRT HOGG DUBÉ SYNDROME  
Shah Richa, 
*
Panchal Hetalkumar, Vaidya Megha
 
G. H. Patel P. G. Department of Computer Sci & Technology, Sardar Patel University, Vallabh Vidyanagar, Gujarat, India–388120 
*Corresponding Author’s E-mail: swamihetal@gmail.com  
Received 15 June 2012; Review Completed 27 June 2012; Accepted 27 June 20122012, Available online 15 July 2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
Birt–Hogg–Dubé (BHD) syndrome is an autosomal, 
dominantly inherited, monogenic condition, characterized  
by the development of fibrofollicu lomas (benign skin 
tumors) on the face, head and upper torso, pulmonary cysts 
and pneumothorax (co llapsed lung), and predisposition to 
kidney cancers with clear cell, chromophobic or oncocytic 
features 
1
. Birt–Hogg–Dubé syndrome affects the skin and 
increases the risk of certain types of tumors. The condition 
is characterized by multip le noncancerous tumors of the 
hair follicles, particu larly on the face, neck, and upper 
chest. These growths typically first appear in a person's 
twenties or thirties. People with Birt–Hogg–Dubé 
syndrome also have an increased risk of developing 
cancerous or noncancerous kidney tumors (chromophobe 
renal cell carcinoma and oncocytoma, respectively) and 
possibly tumors in other organs and tissues. Additionally, 
affected individuals frequently develop cysts in the lungs 
that are at risk to rupture and cause an abnormal collect ion 
of air in the chest cavity (pneumothorax) that may result in 
the collapse of a lung.  In 2001, a BHD-associated gene 
locus was localized to chromosome 17p11.2 
2, 3
 and a 
novel gene, Folliculin (FLCN), was subsequently 
identified as being inactivated in individuals with BHD 
syndrome 
4
.  
BHD gene is also known as FLCN gene. This gene codes 
for a protein called Fo lliculin (FLCN), which has a 
putative tumor suppressor function 
5, 6, 7, 8
. FLCN is 
predicted to encode the 579 amino acid protein FLCN 
(64kDa) 
9
.  Fo lliculin naturally interacts with two proteins 
– Folliculin interacting protein 1(FNIP1) and Follicu lin  
interacting protein 2 (FNIP2) 
10, 11, 12
.  Binding of FLCN to 
FNIP1 and FNIP2 is mediated specifically through the C-
terminal region of FLCN 
10, 11, 12
. In BHD syndrome, the 
majority of mutations were predicted which introduces a 
premature stop codon into FLCN, and therefore result in a 
protein truncation 
13
. However, it is presently unclear 
whether this truncated FLCN is targeted for nonsense-
mediated decay, or remains in the cell with an altered 
function but these mutations remove the ability of FLCN 
to interact with FNIP1 and FNIP2, which suggests that this 
interaction is functionally important. Recently, Baba and 
colleagues identified a novel fo lliculin-interacting protein, 
FNIP1, by co-immunoprecipitation studies in mammalian  
cells. They found that FNIP1 binds to 5’ -AMP activated 
protein kinase, a negative regulator of mTOR suggesting 
that folliculin and its interacting partner may be involved 
in the AMPK and mTOR signalling pathways 
10
. 
FLCN has an essential role in the regulation of 
Transforming Growth Factor-beta (TGF-β) signalling 6. 
FLCN appears to regulate apoptosis through TGF-β-
dependent transcription, which could help to further 
explain the renal cancer phenotype observed in BHD 
syndrome. In nut shell FLCN has been implicated in  
numerous signalling pathways including mTOR and 
AMPK signalling 
14, 10, 15
 Hypoxia Inducible Factor (HIF) 
signalling 
3
, TGF-β signalling 5, 6 and the JAK-STAT 
signalling pathway 
16
. Mutation in FLCN gene increases 
activity of three other genes HIF1A, HIF2A, and TFE3 and 
cause proliferat ion of cell, a typical causative of cancer. 
According to research in past a disulfide compound 
KC7F2 shown to inhibit the proliferat ion of cancer cells 
and decreases Hypoxia Inducible Factor-1 Alpha (HIF-1A) 
levels by down regulating HIF-1A protein synthesis 
17
. 
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From literature it was clear that there were two major 
consequences takes place because of mutated follicu lin  
protein. First is hindrance in formation of FLCN, FNIP1 
and FNIP2 complex which u ltimately interacts with TGF-β 
protein of TGF-β signalling pathway and inactivates tumor 
suppression function of that pathway. The other major 
consequence is activation of HIF1A. From HIF-reporter 
cell-based screening studies of a natural product-like 
chemical library it is suggested that KC7F2 is an inhibitor 
of HIF1A 
17
. Thus here we have focused on another 
inducible factor Hypoxia Inducible Factor-2 A lpha 
(HIF2A) interaction with KC7F2 to carry out in silico  
analysis. A previous study also suggests ability of TSA to 
reverse the biological and molecular defects of BHD cells 
but they have also suggested that further work will be 
needed to elucidate the nature of these effects. So we have 
carried out the work to study the nature of these effects and 
the mode of interaction between Trichostatin A (TSA) and 
TGF-β protein. We found that TSA binds with TGF-β 
protein at same site where the non-mutated follicu lin  
protein was binding and thus the TGF-β protein works 
normally  as a result, anti-pro liferation will takes place via 
p15 protein and ultimately the tumor suppression will 
takes place. Understanding the structure as well as 
interaction will help in treatment. In this study, we 
investigated structure of FLCN, interacting proteins and 
potential ligands which may help in overcoming from the 
BHDS. 
MATERIALS AND METHODS  
Sequence retrieval  
The sequences of FLCN and HIF2A were retrieved from 
one of the largest sequence repository NCBI with sequence 
ID NP_659434.2 and NP_001421.2, respectively.  
Protein Structure modeling & Validation 
Structure of TGF-β is obtained from the Protein Databank  
but structural search of FLCN and HIF2A proteins 
suggested that structures of both proteins were not present 
in Protein Databank (PDB). But we found the modeled  
structure of FLCN by using different template in Protein  
Model Portal. According our studies of Ramachandran plot 
of modeled fo lliculin protein by 2pziA we found that the 
ramachandran plot revealed 63.0% amino acids in 
favoured, 6.2% amino acids in allowed and 1.8% amino 
acids in generously allowed regions which can be 
improved by modeling the protein using other template.  
 
Figure 1: GENE3D representing GABARAP family and 
PRK family as interacting proteins of FLCN 
Thus template based modeling approach using Swiss -PDB 
Viewer (SPDBV) was applied to model the protein 
structure of FLCN. 2p82 (Human cysteine protease 
ATG4A) template was used to model FLCN protein. Same 
template was used to model HIF2A as the sequence 
similarity was good between the HIF2A and 2p82. Further 
to check the quality of the modeled structure, structure 
verification server PROCHECK was utilized and analysis 
of molecular surface and binding cavities of different 
volume and area was done using SPDBV. 
Ligand Finding  
The ligand TSA for TGF-β is retrieved from Drug Bank 
with DB04297 (EXPT03123). Other suggested ligand 
KC7F2 for HIF2A was produced by MarvinSketch by 
using the basic information about it like IUPAC name and 
chemical formula from the literature survey as it was not 
present in any drug databases. It satisfied majority of all 
the Lip inski’s rule of 5.  
 
Figure 2: Produced structure of KC7F2 by using 
MarvinSketch  
Interaction studies 
After identification of binding cavities and the appropriate 
putative ligand, protein-protein interaction and ligand-
receptor interactions was done by using PATCHDOCK 
and FireDock server. 
RES ULTS AND DISCUSS ION 
The structures of protein FLCN and HIF2A were 
modeled by template based modeling using SPDBV tool. 
With the use of PDB specific BLAST appropriate template 
structure was searched which resulted in 6 template 
structures with less than 35% similarity were obtained. 
These 6 structures were used as a template but the 
structure modeled with these templates failed in structure 
validation by ramachandran plot. After this, GENE3D 
gave informat ion about the interacting protein partners of 
Follicu lin. Analysis of interacting proteins of follicu lin  
confirmed GABARAP family and PRK family as its 
interacting partners. Both the above protein s tructures 
showed high sequence similarity with Folliculin (Sequence 
similarity: 54%, Query coverage: 21%) and were used as a 
template to model the folliculin protein. But data of model 
validation represented that folliculin modeled using 
PRKAA1 (pdb id: 2H6D), had ramachandran plot is only 
22.3% which represents a poor structure.  
On the other hand by using GABARAP protein-cysteine 
protease ATG4A (pdb id: 2p82), modeling of fo llicu lin  
show ramachandran plot which represents model of 
acceptable quality. Analysis of ramachandran plot revealed 
88.4% in favoured, 8.4% in allowed and 2.0% in  
generously allowed regions which is also better than the 
modeled structure available in the protein model portal.  
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Figure 3: Comparison of Ramachandran plot results of 
2p82 and 2pziA templates for fo lliculin isoform1 
The modeled structure of folliculin (fig3) and HIF2A are 
deposited in international modeled protein structure 
repository named Protein model database (PMDB) with 
PMID:   PM0078009 and PM0078067, respectively. 
 
Figure 4: Modeled structure of follicu lin isoform 1 using 
2p82 template  
The validation of modeled HIF2A protein through 
Ramachandran plot gave the following results i.e. 88.3% 
amino acids in favoured region, 8.9% amino acids in 
allowed region and 1.8% amino acids in generously 
allowed region. 
The sole purpose of modeling the proteins were to study 
their interactions. The interactions are of TGF-β with 
FLCN and HIF2 with KC7F2, respectively. FLCN in its 
active form works as a tumor suppressor through TGF-β 
pathway but when FLCN is in inactive fo rm because of the 
mutation, it hinders TGF-β pathway and its normal 
function of tumor suppression. Therefore we focused on 
protein-protein interactions study of FLCN with TGF-β 
protein have tried to propose a putative ligand that can 
bind TGF-β at same binding pocket of FLCN and thus can 
reinforce the normal function of TGF-β as tumor 
suppressor. Val441 of FLCN was interacted with ser73 of 
TGF-β and the bond length is 1.1A  between them.  The 
global energy of this interaction is -63.72 kcal/mol 
generated by FireDock. We have found ligand TSA, which 
is HDAC inhibitor and an organic compound used as an 
appropriate ligand to activate the TGF-β signalling 
pathway. We have to treat TGF-β protein with TSA to 
make the TGF-β signalling pathway normal functioning 
and thus it mediate tumor suppressor. 
 
Figure 5: screenshot of FLCN and TGF-β interaction  
TGF-β signalling pathway 
TSA binds with TGF-β protein and then this will further 
binds with TGFβR1. Now this complex will bind with 
smad2 and it phosphorylates smad2 by doing this the 
activity of p15 became active and the level of Bim proteins 
were increased. So, that the work of anti proliferation and 
pro apoptosis is done by p15 and Bim protein, 
respectively. 
 
Proposed-Pathway: TGF-β signaling pathway treating with TSA  
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Ser73 of TGF-β is interacting with TSA. The bond length 
between them is 0.4A . The global energy of this 
interaction is        -44.70kcal/mol. TSA bound on the same 
amino acid where FLCN binds with TGFβ.  From this 
analysis, TSA can be considered as a drug to treat the 
BHDS syndrome. 
 
Figure 6: Screenshot of interaction between TGF-β protein 
and TSA. The ligand (TSA) is in green color and the 
protein which was bound with ligand is in b lue color  
According to the natural function of FLCN it inhibits the 
activity of HIF2A protein. But because of mutation, FLCN 
became inactive and this protein became act ivated which is 
responsible for uncontrolled cell proliferation. Therefore it  
is required to inhibit this protein, as blocking of this 
protein will control the activity of cell proliferation. 
KC7F2 is a chemical drug which is used to block the 
hypoxia response (low oxygen tension). So, we have tried  
to use as a ligand to block the HIF2A protein.  
Interaction of HIF2A with KC7F2 was performed (fig7). 
The interaction shows that Lys503 of HIF2A was 
interacted with KC7F2 with 0.4A   bond length. And the 
global energy produced by FireDock result of this 
interaction is -60.69kcal/mol. 
 
 
Figure 7: Screenshot of interaction between HIF2A-KC7F2 done 
by PATCHDOCK. Amino acid with blue color is interacting 
amino acid of HIF2A with KC7F2 ligand  
CONCLUS ION 
From the present studies we can conclude that the function 
of follicu lin protein is to suppress formation of tumor by 
different pathways. From pathway analysis, different 
reactions were studied to block the proliferat ion of the 
cells which form tumors. By providing the external drug 
like TSA, the process of phosphorylation of SMAD2 is 
done. It activates Bim protein and p15 protein which work 
as pro-apoptotic and anti- proliferat ive, respectively. 
HIF2A is blocked by KC7F2 treatment. So by doing this, 
we may cure the disease. Further web lab analysis of this 
can be done for better understanding of the functioning of 
the suggested treatments. 
ACKNOWLEDGMENT 
I am heartily thankful to Dr. D.B.Choksi, Director, 
G.H.Patel P.G. Department of Computer Science & 
Technology, Sardar Patel University, Vallabh Vidyanagar, 
Gujarat for provid ing me facilit ies platform to exp lore my 
horizons in Bioinformatics.  I am also thankful to Dr. 
Hitesh Shah for providing financial support for publication 
processing charges. 
REFERENCES 
1. Birt AR, Hogg GR and Dubé WJ, Hereditary multiple 
fibrofolliculomas with trichodiscomas and acrochordons, 
Arch Dermatol, 1977, 113, 1674–1677. 
2. Khoo SK, Bradley M, Wong FK, Hedblad MA, Nordenskjöld 
M, Teh BT, Birt-Hogg-Dubé syndrome, mapping of a novel 
hereditary neoplasia gene to chromosome 17p12-q11,2, 
Oncogene, 2001, 20(37),5239-42. 
3. Schmidt LS, Warren MB, Nickerson ML, Weirich G, 
Matrosova V, Toro JR, Turner ML, Duray P, Merino M, 
Hewitt S, Pavlovich CP, Glenn G, Greenberg CR, Linehan 
WM, Zbar B, Birt-Hogg-Dubé syndrome, a genodermatosis 
associated with spontaneous pneumothorax and kidney 
neoplasia, maps to chromosome 17p11,2, Am J Hum Genet, 
2001, 69(4),876-82. 
4. Nagase T, Kikuno R, Ishikawa K, Hirosawa M, Ohara O, 
Prediction of the coding sequences of unidentified human  
genes, XVII, The complete sequences of 100 new cDNA 
clones from brain which code for large proteins in vitro, DNA 
Res, 2000 Apr 28,7(2),143-50. 
5. Cash TP, Gruber JJ, Hartman TR, Henske EP, Simon MC, 
Loss of the Birt-Hogg-Dubé tumor suppressor results in 
apoptotic resistance due to aberrant TGFβ-mediated 
transcription, Oncogene, 2011 Jan 24.  
6. Hong SB, Oh H, Valera VA, Stull J, Ngo DT, Baba M, 
Merino MJ, Linehan WM, Schmidt LS, Tumour suppressor 
FLCN inhibits tumorigenesis of a FLCN-null renal cancer 
cell line and regulates expression of key molecules in TGF-β 
signaling, Molecular Cancer, 2010a 9,160. 
7. Hudon V, Sabourin S, Dydensborg AB, Kottis V, Ghazi A, 
Paquet M, Crosby K, Pomerleau V, Uetani N, Pause A, Renal 
tumour suppressor function of the Birt-Hogg-Dubé syndrome 
gene product folliculin, J Med Genet, 2010 Mar,47(3),182-9.  
8. Vocke CD, Yang Y, Pavlovich CP, Schmidt LS, Nickerson 
ML, Torres-Cabala CA, Merino MJ, Walther MM, Zbar B, 
Linehan WM, High frequency of somatic frameshift BHD 
gene mutations in Birt-Hogg- Dubé -associated renal 
tumours, J Natl Cancer Inst, 2005,97(12),931-5. 
9. Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, 
Turner ML, Duray P, Merino M, Choyke P, Pavlovich CP, 
Sharma N, Walther M, Munroe D, Hill R, Maher E, 
Greenberg C, Lerman MI, Linehan WM, Zbar B, Schmidt LS, 
Mutations in a novel gene lead to kidney tumours, lung wall 
defects, and benign tumours of the hair follicle in patients 
with the Birt-Hogg-Dubé syndrome, Cancer Cell, 2002, 
2(2),157-64. 
10. Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, 
Iwamatsu A, Esposito D, Gillette WK, Hopkins 3rd RF, 
Hartley JL, Furihata M, Oishi S, Zhen W, Burke Jr, TR, 
Linehan WM, Schmidt LS and Zbar B, Folliculin encoded by 
the BHD gene interacts with a binding protein, FNIP1, and 
Panchal et al                                   Journal of Drug Delivery & Therapeutics; 2012, 2(4), 104    108 
© 2011, JDDT. All Rights Reserved                                                         ISSN: 2250-1177                                                    CODEN (USA): JDDTAO 
AMPK, and is involved in AMPK and mTOR signalling, 
Proc Natl Acad Sci USA, 2006, 103,15552–15557. 
11. Hasumi H, Baba M, Hong SB, Hasumi Y, Huang Y, Yao M, 
Valera VA, Linehan WM, Schmidt LS, Identification and 
characterization of a novel folliculin-interacting protein 
FNIP2, Gene, 2008, 415, 60–67. 
12. Takagi Y, Kobayashi T, Shiono M, Wang L, Piao X, Sun G, 
Zhang D, Abe M, Hagiwara Y, Takahashi K, Hino O, 
Interaction of folliculin (Birt–Hogg–Dubé gene product) with 
a novel Fnip1-like (FnipL/Fnip2) protein, Oncogene, 2008 
Sep 11,27(40), 5339–5347. 
13. Singh SR, Zhen W, Zheng Z, Wang H, Oh SW, Liu W, Zbar 
B, Schmidt LS, Hou SX. The Drosophila homolog of the 
human tumour suppressor gene BHD interacts with the JAK-
STAT and Dpp signaling pathways in regulating male 
germline stem cell maintenance. Oncogene. 2006 Sep 
28;25(44):5933- 41. 
14. Baba M, Furihata M, Hong SB, Tessarollo L, Haines DC, 
Southon E, Patel V, Igarashi P, Alvord WG, Leighty R, Yao 
M, Bernardo M, Ileva L, Choyke P, Warren MB, Zbar B, 
Linehan WM, Schmidt LS, Kidney-targeted Birt-Hogg-Dubé 
gene inactivation in a mouse model, Erk1/2 and Akt-mTOR 
activation, cell hyperproliferation, and polycystic kidneys, J 
Natl Cancer Inst, 2008 100(2),140- 54. 
15. Vanhaecke T, Papeleu P, Elaut G, Rogiers V (2004), 
"Trichostatin A-like hydroxamate histone deacetylase 
inhibitors as therapeutic agents, toxicological point of view", 
Curr Med Chem 11 (12), 1629–43, PMID 15180568. 
16. Singh SR, Zhen W, Zheng Z, Wang H, Oh SW, Liu W, Zbar 
B, Schmidt LS, Hou SX, The Drosophila homolog of the 
human tumour suppressor gene BHD interacts with the JAK-
STAT and Dpp signaling pathways in regulating male 
germline stem cell maintenance, Oncogene, 2006 Sep 
28,25(44),5933- 41. 
17. Mei Yee Koh, Taly R, Spivak-Kroizman and Garth 
Powis,Inhibiting the Hypoxia Response for Cancer Therapy, 
The New Kid on the Block Clin Cancer Res 2009,15,5945-
5946, Published OnlineFirst September 29, 2009. 
